Limitations in current treatment options, particularly in LGG and AML, due to both inefficacy and systemic toxicity, make mutant IDH (mutIDH), and its associated molecular pathways attractive therapeutic targets (7–9). The gene discussed is IDH1; the disease is acute myeloid leukemia.